Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.59 |
| ▸ | TACR1 | P25103 | 6/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | MC4R | P32245 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1171130 | 0.98 | SIGMAR1 (0.57) | SIGMAR1TACR1HRH3MC4RGAA | |
| SCHEMBL1713728 | 0.96 | SIGMAR1 (0.63) | SIGMAR1TACR1HRH3MC4RGAA | |
| SCHEMBL11172583 | 0.95 | HRH3 (0.57) | SIGMAR1TACR1HRH3LMNAPOLB | |
| SCHEMBL4055438 | 0.93 | HRH3 (0.59) | SIGMAR1HRH3MC4RLMNAPOLB | |
| SCHEMBL4726 | 0.93 | SIGMAR1 (0.68) | SIGMAR1TACR1MC4RGAADRD4 | |
| Iodide SCHEMBL1697595 | 0.91 | SIGMAR1 (0.65) | SIGMAR1TACR1MC4RGAADRD4 | |
| Hydrochloric Acid SCHEMBL5671727 | 0.91 | SIGMAR1 (0.65) | SIGMAR1TACR1MC4RGAADRD4 | |
| Iodomethane SCHEMBL7490412 | 0.87 | SIGMAR1 (0.61) | SIGMAR1TACR1MC4RGAADRD4 | |
| SCHEMBL568477 | 0.86 | SIGMAR1 (0.53) | SIGMAR1MC4R | |
| Butane SCHEMBL11362529 | 0.86 | SIGMAR1 (0.59) | SIGMAR1TACR1MC4RGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 186 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630487-B2 | Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2026-05-19 | — | — | US | disclosed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4076450-B1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-12371442-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3939954-B1 | METHOD FOR INTRODUCING DEUTERATED LOWER ALKYL INTO AMINE MOIETY OF COMPOUND CONTAINING SECONDARY AMINE | OTSUKA PHARMA CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-12202843-B2 | Muscarinic receptor agonists | NXERA PHARMA UK LIMITED (GB) | 2025-01-21 | — | — | US | disclosed |
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | CALICO LIFE SCIENCES LLC (US) | 2024-12-26 | — | — | US | disclosed |
| WO-1997048702-A1 | BENZAZEPINE DERIVATIVES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1997-12-24 | — | — | WO | disclosed |
| WO-1997032880-A1 | PYRIMIDO[5,4-D]PYRIMIDINES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PRODUCTION | DR. KARL THOMAE GMBH (DE) | 1997-09-12 | — | — | WO | disclosed |
| US-4486433-A | SLOWING HEART RATE | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1984-12-04 | — | — | US | disclosed |
| EP-0047412-B1 | PYRAZINES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1984-07-25 | — | — | EP | disclosed |
| US-4409220-A | Fused-ring amino-pyrazines as bradycardiac agents | DR. KARL THOMAE GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-10-11 | — | — | US | disclosed |
| US-4377581-A | ANTIHYPERTENSIVE AGENTS | PFIZER INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4351940-A | Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines | PFIZER INC. (US) | 1982-09-28 | — | — | US | disclosed |
| EP-0047412-A1 | Pyrazines, their preparation and pharmaceutical compositions containing them | Dr. Karl Thomae GmbH (DE) | 1982-03-17 | — | — | EP | disclosed |
| US-4287341-A | USEFUL AS ANTIHYPERTENSIVE AGENTS | PFIZER INC. (US) | 1981-09-01 | — | — | US | disclosed |
| US-3987047-A | ANORETICS | BOEHRINGER INGELHEIM GMBH (DT) | 1976-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12202843-B2 | Muscarinic receptor agonists | CHRM1, CHRM2, CHRM3 | SIGMAR1 197/4885TACR1 57/4885HRH3 95/4885 |
| US-20240424111-A1 | Degrader Compounds and Uses Thereof | PTPN1, PTPN2, PTPN5 | SIGMAR1 2225/4885TACR1 2723/4885HRH3 4653/4885 |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | SIGMAR1 3180/4885TACR1 4574/4885HRH3 2838/4885 |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | SIGMAR1 3180/4885TACR1 4574/4885HRH3 2838/4885 |
| US-12630487-B2 | Method for introducing deuterated lower alkyl into amine moiety of compound containing secondary amine | AZI2, ALKBH2, MGMT | SIGMAR1 1641/4885TACR1 3001/4885HRH3 338/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | SIGMAR1 734/4885TACR1 3741/4885HRH3 1379/4885 |
| US-12371442-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | SIGMAR1 3180/4885TACR1 4574/4885HRH3 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.